The SARM1 targeting therapeutics market is projected to grow at a CAGR of 102.1%

SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share

The SARM1 targeting therapeutics market is projected to grow at a CAGR of 102.1%

SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share. Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide.

The SARM1 targeting therapeutics market is projected to grow at a CAGR of 102.1%

SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share. Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide.